Arca
Skip to content
Tools
Tools

Kaposi sarcoma

Drug research and approvals for kaposi sarcoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 25 studies of kaposi sarcoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 1 approved and 2 open orphan designations naming it.

  • Recruiting worldwide: 25
  • Trials authorized in Canada: 0
  • FDA orphan approvals: 1
  • EU medicines: 0

Recruiting now

Newest posted first, of 25 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 4

Phase 3 3

Phase 2 12 of 21

  • PomalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
  • BevacizumabVascular endothelial growth factor A inhibitor
  • IndinavirHuman immunodeficiency virus type 1 protease inhibitor
  • PembrolizumabProgrammed cell death protein 1 inhibitor
  • SEPHB4-HSAEphrin-B2 inhibitor
  • AbacavirHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
  • EverolimusFK506-binding protein 1A inhibitor
  • LamivudineHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
  • MaravirocC-C chemokine receptor type 5 antagonist
  • PropranololBeta-1 adrenergic receptor antagonist
  • RitonavirHuman immunodeficiency virus type 1 protease inhibitor
  • SunitinibMacrophage colony stimulating factor receptor inhibitor

Phase 1 or earlier 9

How its trials ended

159 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 25 whose ending is known, 32% met their primary endpoint, 8% missed it and 60% stopped early.

  • Completed, result not reported9459%
  • Ongoing3321%
  • Met its primary endpoint85%
  • Status unknown74%
  • Stopped: enrollment or feasibility53%
  • Stopped: other or unclear53%
  • Missed its primary endpoint21%
  • Stopped: sponsor or business decision21%
  • Stopped: lack of efficacy11%
  • Stopped: safety11%
  • Stopped: funding11%

FDA orphan designations

Approved first, then open designations, newest first
May 14, 2020Pomalyst®POMALYST (pomalidomide) is indicated for the treatment of adult patients with AIDS-related Kaposi sarcoma (KS) after failure of highly…Celgene CorporationApproved
Jan 12, 2021AlitretinoinTreatment of systemic (non-cutaneous) kaposi sarcomaGalephar Pharmaceutical Research, Inc.Designated
Sep 20, 2012H-Leu-Pro-Pro-Ser-Arg-OHTreatment of Kaposi sarcomaImmuno Tech, Inc.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.